Personalized DC Vaccine for Lung Cancer

Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer

The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.

Inclusion Criteria:

• pathologically confirmed non-small cell lung cancer
• failed in previous standard chemotherapy and targeted therapy
• anticipated life time > 3month
• Karnofsky performance status 0-1
• rehabilitate from previous therapy
• adequate organ functions

Exclusion Criteria:

• mixed histological types
• tumor emergency
• abnormal coagulation condition
• contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
• concomitant tumors
• immunological co-morbidities